REG - Hutchmed China Ltd - Notice of Results

HUTCHMED (China)Announcement

19/02/2025 08:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250219:nRSS5549Xa&default-theme=true

RNS Number : 5549X  Hutchmed (China) Limited  19 February 2025

HUTCHMED to Announce 2024 Final Results

 

Hong Kong, Shanghai & Florham Park, NJ - Wednesday, February 19, 2025:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year
ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern
Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong
Time (HKT).

 

Analysts and investors are invited to join a conference call and audio webcast
presentation with Q&A, conducted by HUTCHMED management.

 

The English conference call and audio webcast will take place at 8:00 am EDT /
12:00 pm GMT / 8:00 pm HKT on Wednesday, March 19, 2025.  In addition to the
usual English webcast, there will also be a Chinese (Putonghua) webcast at
12:30 am GMT / 8:30 am HKT on Thursday, March 20, 2025 (8:30 pm EDT on
Wednesday, March 19, 2025).  Both webcasts will be available live via the
company website at www.hutch-med.com/event/ (https://www.hutch-med.com/event/)
. The presentation will be available for downloading before the conference
call begins. Details of the conference call dial-in will be provided in the
financial results announcement and on the company website.  A replay will
also be available on the website shortly after the event.

 

About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit:
www.hutch‑med.com (https://www.hutch-med.com/)
 or follow us on
LinkedIn (https://www.linkedin.com/company/hutchmed/)
.

 

CONTACTS
 Investor Enquiries                                   +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                     +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                      (mailto:HUTCHMED@fticonsulting.com)
     Ben Atwell / Alex Shaw                               +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
 Brunswick - Zhou Yi                                  +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                      (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                      Nominated Advisor and Joint Broker
 Atholl Tweedie / Freddy Crossley / Rupert Dearden    +44 20 7886 2500

 HSBC                                                 Joint Broker
 Simon Alexander / Alina Vaskina / Arnav Kapoor       +44 20 7991 8888

 Cavendish                                            Joint Broker
 Geoff Nash / Nigel Birks                             +44 20 7220 0500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORLVLFFELLBBBX